Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: Updated results of the CAO/ARO/AIO-94 trial

Journal of Clinical Oncology

Volumn 32, Issue 15, 2014, Pages 1554-1562

  Fokas, Emmanouil ^a   Liersch, Torsten ^b   Fietkau, Rainer ^c   Hohenberger, Werner ^c   Beissbarth, Tim ^b   Hess, Clemens ^b   Becker, Heinz ^b   Ghadimi, Michael ^b   Mrak, Karl ^f   Merkel, Susanne ^c   Raab, Hans Rudolf ^d   Sauer, Rolf ^c   Wittekind, Christian ^e   Rod̈el, Claus ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d KLINIKUM OLDENBURG   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CANCER CELL; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECTUM CARCINOMA; REPRODUCIBILITY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR REGRESSION; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FIBROSIS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RECTUM TUMOR; REMISSION; RISK FACTOR; TIME; TUMOR INVASION; TUMOR RECURRENCE;

CARCINOMA; CHEMORADIOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FIBROSIS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903776571     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.3769     Document Type: Article

References (54)

1. Rodel C, Hofheinz R, Liersch T: Rectal cancer: State of the art in 2012. Curr Opin Oncol 24:441-447, 2012
2. McCarthy K, Pearson K, Fulton R, et al: Preoperative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev 12:CD008368, 2012
3. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731-1740, 2004
4. Sauer R, Liersch T, Merkel S, et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926-1933, 2012
5. Mamon HJ: Long-term follow-up of a paradigm-changing study: The paradigm still holds. J Clin Oncol 30:1901-1903, 2012
6. Chetty R, Gill P, Bateman AC, et al: Pathological grading of regression: An International Study Group perspective. J Clin Pathol 65:865-866, 2012
7. Chetty R, Gill P, Govender D, et al: International study group on rectal cancer regression grading: Interobserver variability with commonly used regression grading systems. Hum Pathol 43:1917-1923, 2012
8. Janjan NA, Khoo VS, Abbruzzese J, et al: Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M. D. Anderson Cancer Center experience Int J Radiat Oncol Biol Phys 44:1027-1038, 1999 (Pubitemid 29342903)
9. Valentini V, Coco C, Picciocchi A, et al: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53:664-674, 2002 (Pubitemid 34626505)
10. Rödel C, Martus P, Papadoupolos T, et al: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688-8696, 2005 (Pubitemid 46211512)
11. Das P, Lin EH, Bhatia S, et al: Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: A matched-pair analysis. Int J Radiat Oncol Biol Phys 66:1378-1383, 2006
12. Kuo LJ, Liu MC, Jian JJ, et al: Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol 14:2766-2772, 2007 (Pubitemid 47460637)
13. Hughes R, Glynne-Jones R, Grainger J, et al: Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision? Int J Colorectal Dis 21:11-17, 2006 (Pubitemid 41829760)
14. García-Aguilar J, Hernandez de Anda E, Sirivongs P, et al: A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 46:298-304, 2003 (Pubitemid 36331646)
15. Suárez J, Vera R, Balén E, et al: Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis 10:563-568, 2008 (Pubitemid 351803062)
16. Park IJ, You YN, Agarwal A, et al: Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 30:1770-1776, 2012
17. Shivnani AT, Small W Jr, Stryker SJ, et al: Preoperative chemoradiation for rectal cancer: Results of multimodality management and analysis of prognostic factors. Am J Surg 193:389-393, 2007; discussion 393-394
18. Goethals L, Haustermans K, Perneel C, et al: Chemo-radiotherapy versus radiotherapy alone in the pre-operative treatment of resectable rectal cancer. Eur J Surg Oncol 31:969-976, 2005 (Pubitemid 41671110)
19. Mohiuddin M, Hayne M, Regine WF, et al: Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 48:1075-1080, 2000
20. Quah HM, Chou JF, Gonen M, et al: Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 113:57-64, 2008 (Pubitemid 351976386)
21. Chari RS, Tyler DS, Anscher MS, et al: Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 221: 778-786, 1995; discussion 786-787
22. Stipa F, Chessin DB, Shia J, et al: A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol 13:1047-1053, 2006 (Pubitemid 44337963)
23. Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19-23, 1997 (Pubitemid 27138353)
24. Hermanek P, Sobin LH (eds): International Union Against Cancer (UICC): TNM Classification of Malignant Tumours (ed 4). Berlin, Springer-Verlag, 1987
25. Rödel C, Liersch T, Becker H, et al: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13:679-687, 2012
26. Mohiuddin M, Regine WF, John WJ, et al: Preoperative chemoradiation in fixed distal rectal cancer: Dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys 46:883-888, 2000 (Pubitemid 30114400)
27. Francois Y, Nemoz CJ, Baulieux J, et al: Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 17:2396, 1999
28. Wolthuis AM, Penninckx F, Haustermans K, et al: Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol 19:2833-2841, 2012
29. Maas M, Nelemans PJ, Valentini V, et al: Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol 11:835-844, 2010
30. Bonnetain F, Bosset JF, Gerard JP, et al: What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? Eur J Cancer 48:1781-1790, 2012
31. Malumbres M, Barbacid M: RAS oncogenes: The first 30 years. Nat Rev Cancer 3:459-465, 2003 (Pubitemid 37328850)
32. McKenna WG, Muschel RJ, Gupta AK, et al: The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 22:5866-5875, 2003 (Pubitemid 37176707)
33. Kurrey NK, Jalgaonkar SP, Joglekar AV, et al: Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27:2059-2068, 2009
34. Tsuji T, Ibaragi S, Hu GF: Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 69:7135-7139, 2009
35. Mehrotra S, Languino LR, Raskett CM, et al: IAP regulation of metastasis. Cancer Cell 17:53-64, 2010
36. Moussata D, Amara S, Siddeek B, et al: XIAP as a radioresistance factor and prognostic marker for radiotherapy in human rectal adenocarcinoma. Am J Pathol 181:1271-1278, 2012
37. Vaupel P: Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14:198-206, 2004
38. Bertout JA, Patel SA, Simon MC: The impact of O2 availability on human cancer. Nat Rev Cancer 8:967-975, 2008
39. Semenza GL: Oxygen sensing, homeostasis, and disease. N Engl J Med 365:537-547, 2011
40. Sprenger T, Rödel F, Beissbarth T, et al: Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res 17:1623-1631, 2011
41. Rödel F, Hoffmann J, Distel L, et al: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65:4881-4887, 2005 (Pubitemid 40740827)
42. Capalbo G, Rödel C, Stauber RH, et al: The role of survivin for radiation therapy: Prognostic and predictive factor and therapeutic target. Strahlenther Onkol 183:593-599, 2007 (Pubitemid 350124276)
43. Hehlgans S, Petraki C, Reichert S, et al: Double targeting of survivin and XIAP radiosensitizes 3D grown human colorectal tumor cells and decreases migration. Radiother Oncol 108:32-39, 2013
44. Kang Y, Pantel K: Tumor cell dissemination: Emerging biological insights from animal models and cancer patients. Cancer Cell 23:573-581, 2013
45. Comen E, Norton L, Massagué J: Clinical implications of cancer self-seeding. Nat Rev Clin Oncol 8:369-377, 2011
46. Klein CA: Parallel progression of primary tumours and metastases. Nat Rev Cancer 9:302-312, 2009
47. Formenti SC, Demaria S: Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst 105:256-265, 2013
48. Marquardt F, Rödel F, Capalbo G, et al: Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol 185:371-378, 2009
49. Wadlow RC, Ryan DP: The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer 116:3537-3548, 2010
50. Petersen C: Optimal timing of surgery for rectal cancer after neoadjuvant chemoradiotherapy: Which patients would benefit from waiting? [in German]. Strahlenther Onkol 189:904-906, 2013
51. Collette L, Bosset JF, den Dulk M, et al: Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: Does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 25:4379-4386, 2007 (Pubitemid 350013843)
52. Mandard AM, Dalibard F, Mandard JC, et al: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: Clinicopathologic correlations. Cancer 73:2680-2686, 1994 (Pubitemid 24166250)
53. Wheeler JM, Warren BF, Mortensen NJ, et al: Quantification of histologic regression of rectal cancer after irradiation: A proposal for a modified staging system. Dis Colon Rectum 45:1051-1056, 2002
54. Washington MK, Berlin J, Branton P, et al: Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med 133:1539-1551, 2009